Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magali Lacroix

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Nature Medicine|September 4, 2025
Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trialBarbara Pistilli, Fernanda Mosele, Noemie Corcos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 20, 2019
Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion studyHélène Dano, Serdar Altinay, Laurent Arnould, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2021
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA studyMieke R Van Bockstal, Aline François, Serdar Altinay, et al.
Nature Medicine|October 27, 2014
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapyAntonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain TumorsShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Nature Medicine|September 4, 2025
Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trialBarbara Pistilli, Fernanda Mosele, Noemie Corcos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 20, 2019
Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion studyHélène Dano, Serdar Altinay, Laurent Arnould, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 4, 2021
Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA studyMieke R Van Bockstal, Aline François, Serdar Altinay, et al.
Nature Medicine|October 27, 2014
Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapyAntonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further ResearchShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Advances in Anatomic Pathology|August 5, 2017
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain TumorsShona Hendry, Roberto Salgado, Thomas Gevaert, et al.
Pageof 12